Blog Layout

Telehealth Expansion: Investment Opportunities and Market Dynamics

July 28, 2024

The rise of telehealth services marks a significant shift in the healthcare landscape, driven by technological advancements and changing patient needs. Telehealth, encompassing a range of services from video consultations to remote monitoring, has gained unprecedented importance in modern healthcare. This blog explores the rapid growth and expansion of telehealth services, examining the trends, market dynamics, and investment opportunities that define this burgeoning sector.


Telehealth refers to the delivery of healthcare services through digital and telecommunication technologies, enabling remote patient care, consultations, and monitoring. It includes video consultations, telemedicine platforms, remote monitoring devices, and mobile health apps. These technologies offer numerous benefits, including improved access to care, enhanced patient engagement, and cost-effective healthcare delivery.

The scope of telehealth is broad, encompassing various components such as:


  • Video Consultations: Enable real-time interactions between patients and healthcare providers, facilitating diagnoses and follow-up care without the need for in-person visits.
  • Remote Monitoring: Utilizes devices to track patient health metrics such as heart rate, blood pressure, and glucose levels, allowing continuous monitoring and timely interventions.
  • Telemedicine Platforms: Provide a comprehensive suite of services, including electronic health records (EHR), appointment scheduling, and patient management tools.


The benefits of telehealth for patients and healthcare providers are manifold. Patients gain improved access to care, especially in rural and underserved areas, reduced travel time and costs, and greater convenience. Healthcare providers benefit from increased efficiency, the ability to monitor patients more effectively, and reduced strain on healthcare facilities.


Market Dynamics of Telehealth


The telehealth market has experienced significant growth, driven by several key factors. According to market research, the global telehealth market is projected to reach $559.52 billion by 2027, growing at a compound annual growth rate (CAGR) of 25.2% from 2020 to 2027.


  • Increased Demand for Remote Care: The COVID-19 pandemic has accelerated the adoption of telehealth, as patients and providers sought safe alternatives to in-person visits.
  • Technological Advancements: Innovations in digital technology, including AI, IoT, and 5G connectivity, have enhanced the capabilities and reliability of telehealth services.
  • Healthcare Accessibility: Telehealth bridges the gap in healthcare access for patients in remote and underserved areas, offering them timely and convenient care.


The telehealth market is highly competitive, with numerous players offering diverse solutions. Major companies include Teladoc Health, Amwell, and Doctor on Demand, alongside emerging startups like Lemonaid Health and Hims & Hers. These companies differentiate themselves through innovative technologies, comprehensive service offerings, and strategic partnerships.


Technological Advancements in Telehealth


Technological innovations are at the core of telehealth's rapid expansion. Key advancements include:


AI and Machine Learning

AI and machine learning enhance telehealth services by enabling predictive analytics, personalized treatment plans, and efficient patient triage. These technologies can analyze large datasets to identify patterns and provide insights, improving diagnostic accuracy and treatment outcomes.


IoT and 5G Connectivity

The Internet of Things (IoT) facilitates seamless connectivity between devices, allowing real-time data collection and monitoring. 5G connectivity enhances the speed and reliability of telehealth services, supporting high-quality video consultations and remote monitoring.


Integration of Electronic Health Records (EHR)

Integrating EHR with telehealth platforms ensures comprehensive patient data is readily accessible, improving care coordination and continuity. EHR integration also supports efficient documentation and billing processes.


Wearable Devices and Remote Monitoring Tools

Wearable devices, such as smartwatches and fitness trackers, play a crucial role in remote patient monitoring. These devices continuously collect health data, providing valuable insights into patient health and enabling timely interventions.


Regulatory Changes and Policies


Regulatory frameworks play a critical role in shaping the telehealth landscape. Key regulations affecting telehealth include:


HIPAA and GDPR

The Health Insurance Portability and Accountability Act (HIPAA) in the United States and the General Data Protection Regulation (GDPR) in Europe set stringent standards for data privacy and security. Compliance with these regulations is essential for telehealth providers to ensure patient data is protected.


Recent Regulatory Changes

The COVID-19 pandemic prompted regulatory bodies to relax certain restrictions on telehealth, facilitating its rapid adoption. For instance, the U.S. government expanded Medicare coverage for telehealth services, allowing more patients to access remote care.


Challenges in Navigating Telehealth Regulations

Navigating the complex regulatory landscape poses challenges for telehealth providers. Ensuring compliance with diverse regulations across different regions requires significant resources and expertise. Additionally, ongoing changes in regulations necessitate continuous monitoring and adaptation.


Trends in Telehealth Expansion


Growth During the COVID-19 Pandemic

The COVID-19 pandemic catalyzed the widespread adoption of telehealth, with many healthcare providers and patients embracing remote care. The need for social distancing and minimizing exposure to the virus drove the shift towards telehealth services, resulting in a dramatic increase in usage.


Rise of Specialty Telehealth Services

Specialty telehealth services, such as mental health, dermatology, and chronic disease management, have gained traction. These services cater to specific patient needs, offering tailored care and expertise. For example, mental health telehealth platforms provide accessible and convenient therapy sessions, addressing the growing demand for mental health services.


Adoption in Rural and Underserved Areas

Telehealth has significantly improved healthcare access in rural and underserved areas, where medical facilities and specialists may be scarce. Remote consultations and monitoring enable patients in these regions to receive timely and quality care, reducing healthcare disparities.


Investment Opportunities in Telehealth


Investing in telehealth offers significant potential, given the sector's rapid growth and innovation. Investors should look for companies with strong technological capabilities, a robust customer base, and a clear value proposition. Promising areas include AI-driven telehealth solutions, remote monitoring technologies, and integrated telemedicine platforms.


Factors to Consider When Investing in Telehealth

Investors should evaluate several factors when considering telehealth investments:


  • Market Potential: Assess the target market's size and growth prospects.
  • Technology Differentiation: Determine the uniqueness and scalability of the technology.
  • Regulatory Compliance: Ensure the company adheres to relevant regulations and standards.
  • Business Model: Analyze the company's revenue streams and profitability.


Long-term vs. Short-term Investment Strategies

Long-term investments in telehealth can yield substantial returns as the sector continues to evolve and expand. Investors should focus on companies with sustainable business models, innovative technologies, and strong market positions. Short-term opportunities may arise from mergers and acquisitions, regulatory changes, or technological breakthroughs.


Recent investments in telehealth highlight the sector's potential. For instance, Teladoc Health's acquisition of Livongo for $18.5 billion in 2020 created a comprehensive virtual care platform, integrating chronic condition management with telehealth services. This strategic move positioned Teladoc as a leader in the telehealth market, driving significant growth and market penetration.


Notable Labs: Pioneering Precision Medicine Integration in Health Insurance


Notable Labs stands at the forefront of integrating precision medicine into healthcare, demonstrating how advanced genetic and molecular analyses can be seamlessly incorporated into standard healthcare coverage. This innovative approach addresses the diverse and complex needs of patients by tailoring treatments based on individual genetic profiles. By leveraging these advanced techniques, Notable Labs collaborates with insurers and healthcare providers to pioneer innovative approaches that ensure precision medicine treatments are accessible and affordable for all patients.


The commitment of Notable Labs to evidence-based practices and robust clinical data supports the development of reimbursement policies that recognize the value and cost-effectiveness of precision medicine. These policies are crucial for broadening access to personalized treatments, making them a viable option for a wider patient population. Notable Labs exemplifies the potential for precision medicine to transform patient care and improve health outcomes, setting a new standard for integrating cutting-edge medical advancements into everyday healthcare.


One of the key aspects of Notable Labs’ strategy is the emphasis on collaboration with insurers. By working closely with insurance companies, Notable Labs helps to create reimbursement frameworks that reflect the actual benefits of precision medicine. This collaboration ensures that insurers understand the long-term cost savings and improved patient outcomes associated with personalized treatments. These partnerships are essential for overcoming financial barriers and making precision medicine more widely available.


In addition to working with insurers, Notable Labs also partners with healthcare providers to integrate precision medicine into clinical practice. This integration involves training healthcare professionals on the latest genetic and molecular analysis techniques, ensuring they are equipped to deliver personalized care. By providing healthcare providers with the tools and knowledge necessary to utilize precision medicine effectively, Notable Labs enhances the overall quality of patient care.


Notable Labs’ approach to precision medicine extends beyond treatment to include prevention and early diagnosis. By identifying genetic predispositions to certain diseases, healthcare providers can implement early intervention strategies, potentially preventing the onset of serious conditions. This proactive approach not only improves patient outcomes but also reduces healthcare costs by avoiding expensive treatments and hospitalizations.

The use of precision medicine also allows for more accurate diagnoses, reducing the likelihood of misdiagnosis and inappropriate treatments. This accuracy leads to more effective treatment plans, as therapies can be tailored to target the specific genetic mutations driving a patient’s condition. The result is a higher success rate for treatments and a reduction in the trial-and-error approach often associated with traditional medicine.


Notable Labs is also at the cutting edge of research and development in precision medicine. By conducting clinical trials and research studies, they contribute to the growing body of knowledge in the field. These efforts help to validate new treatments and approaches, providing the evidence needed to support wider adoption of precision medicine. The company’s commitment to research ensures that they remain leaders in the field, continually pushing the boundaries of what is possible in personalized healthcare.


Moreover, Notable Labs’ dedication to data security and patient privacy is paramount. The integration of genetic and molecular data into healthcare systems necessitates stringent data protection measures. Notable Labs employs advanced encryption and security protocols to safeguard patient information, ensuring that sensitive data is protected against unauthorized access. This commitment to data security builds trust with patients and healthcare providers, facilitating the adoption of precision medicine.


As a leader in the field, Notable Labs is paving the way for a future where personalized healthcare is the norm, ensuring that each patient receives the most effective and individualized treatment possible. Their pioneering work in integrating precision medicine into healthcare demonstrates the transformative potential of this approach, setting a new standard for patient care. By making precision medicine accessible and affordable, Notable Labs is not only improving health outcomes but also reshaping the healthcare landscape for the better.


The impact of Notable Labs’ work extends beyond individual patients to the healthcare system as a whole. By promoting the adoption of precision medicine, they are driving a shift towards more efficient and effective healthcare. This shift has the potential to reduce overall healthcare costs, as personalized treatments can prevent complications and reduce the need for expensive interventions. The broader adoption of precision medicine also encourages further innovation and investment in the field, fostering a cycle of continuous improvement.


In conclusion, Notable Labs exemplifies the potential of precision medicine to revolutionize healthcare. Through their collaboration with insurers and healthcare providers, commitment to evidence-based practices, and focus on patient-centric care, they are setting a new standard for integrating advanced medical technologies into everyday healthcare. Their pioneering efforts are paving the way for a future where personalized healthcare is accessible to all, ensuring that each patient receives the most effective and individualized treatment possible. Notable Labs’ work is a testament to the transformative power of precision medicine and its ability to improve patient outcomes and reshape the healthcare landscape.


Case Studies of Successful Telehealth Companies

Teladoc Health

Teladoc Health is a pioneer in the telehealth industry, offering a wide range of virtual care services. The company's innovative approach and strategic acquisitions have propelled its growth, making it a market leader. Teladoc's comprehensive platform integrates telehealth, mental health, and chronic disease management, delivering holistic care to patients worldwide.


Amwell

Amwell, another prominent telehealth provider, has made significant strides in expanding its services. The company's telehealth platform connects patients with healthcare providers through video consultations, remote monitoring, and digital tools. Amwell's partnerships with major health systems and insurers have enhanced its market presence and accessibility.


Doctor on Demand

Doctor on Demand focuses on providing accessible and affordable healthcare through its telemedicine platform. The company's user-friendly app enables patients to consult with board-certified physicians, mental health professionals, and specialists. Doctor on Demand's emphasis on quality care and convenience has driven its success and market growth.


Lessons Learned from These Case Studies

These companies' success underscores the importance of innovation, strategic partnerships, and a patient-centric approach in the telehealth industry. By leveraging advanced technologies and addressing patient needs, telehealth providers can achieve significant market penetration and growth.


Challenges and Risks



Despite its potential, telehealth faces several challenges and risks. Technical issues, such as connectivity problems and software malfunctions, can disrupt services and impact patient care. Data privacy and security concerns are paramount, as telehealth platforms handle sensitive patient information. Ensuring robust cybersecurity measures is crucial to maintaining patient trust and compliance with regulations.


Navigating the complex regulatory landscape poses challenges for telehealth providers. Compliance with diverse regulations across different regions requires significant resources and expertise. Additionally, ongoing changes in regulations necessitate continuous monitoring and adaptation.


Telehealth providers can mitigate risks and overcome barriers by investing in robust infrastructure, adopting best practices for data privacy and security, and fostering partnerships with regulatory bodies. Engaging patients and healthcare providers in the development and implementation of telehealth solutions can also enhance acceptance and adoption.


Future Trends and Innovations


The telehealth sector is poised for continued growth and innovation. Emerging trends include the integration of AI and machine learning for predictive analytics, the expansion of remote monitoring capabilities, and the development of personalized care plans. Additionally, telehealth providers are exploring new service offerings, such as virtual reality therapy and remote surgical consultations.Technological advancements will continue to shape the future of telehealth. The deployment of 5G networks will enhance connectivity and enable real-time, high-quality video consultations. Advances in AI and data analytics will improve diagnostic accuracy and treatment outcomes. Wearable devices and remote monitoring tools will provide continuous health data, enabling proactive and preventive care.


Over the next decade, telehealth is expected to become an integral part of healthcare delivery. The sector will see increased adoption across various medical specialties, expanded access in rural and underserved areas, and greater integration with traditional healthcare systems. Telehealth providers will continue to innovate, offering new services and improving patient care. The rapid expansion of telehealth services marks a significant transformation in healthcare delivery. Telehealth offers numerous benefits, including improved access to care, enhanced patient engagement, and cost-effective healthcare delivery. Despite challenges and risks, the potential of telehealth to revolutionize healthcare is undeniable.

A nurse is holding a bottle of pills in her hand.
July 29, 2024
Discover how HealthTech innovations are transforming chronic disease management. This blog highlights the latest technologies like remote monitoring, AI, and mobile apps, which improve patient care, outcomes, and reduce costs. Explore real-world examples and see how personalized and preventive approaches enhance quality of life for millions.
A female doctor wearing a white coat with a stethoscope around her neck.
By Daniel Ferry July 29, 2024
Notable Labs is a clinical-stage precision oncology company developing new cancer therapies identified by its Predictive Medicine Platform (PMP), today announced progress for the Phase 2 volasertib program following receipt of “Clearance to Proceed” from the FDA and agreement on the dosing plan for its Phase 2 clinical trial. With trial start-up activities launched in the first quarter of this year, Notable intends to initiate enrollment in the Phase 2 study for PMP-enabled development of volasertib for relapsed refractory (R/R) acute myeloid leukemia (AML) in the coming months.
A man in a lab coat and mask is holding a box of test tubes.
By Syeda Abeer Iqbal July 29, 2024
Notable Labs is transforming pediatric leukemia treatment with its Predictive Precision Medicines Platform (PPMP), which boasts a 97% predictive precision. This platform rapidly identifies the most effective treatments for individual patients, significantly reducing the time and cost of cancer therapy. Notable Labs focuses on personalized medicine, combining high-throughput screening and machine learning to predict patient responses and tailor treatments accordingly. Their innovative approach has shown promising results in clinical validation studies, offering new hope for improving outcomes in pediatric leukemia.
A man in a lab coat is pushing a cart down a hallway.
By Scott Smith July 29, 2024
Notable Labs is revolutionizing cancer treatment with its innovative approach to combination therapy, which targets multiple cancer pathways simultaneously. Their Predictive Precision Medicine Platform (PPMP) leverages advanced data analysis and machine learning to identify the most effective drug combinations for individual patients. By using high-throughput screening and bio-simulation, Notable Labs accelerates drug development, reduces costs, and improves clinical trial success rates. This approach promises significant improvements in patient outcomes, particularly for pediatric leukemia, by providing personalized, effective treatments and minimizing side effects.
A woman is laying in a dental chair in a dark room looking up.
By Ayushi Hisaria July 29, 2024
Notable Labs' cutting-edge diagnostic technology, boasting a 95% prediction accuracy per a Stanford study, is set to revolutionize pediatric leukemia treatment by identifying the most effective therapies. Their mission centers on advancing precision diagnostics to enhance therapy efficacy for young patients. Utilizing high-throughput screening and machine learning, Notable's platform offers tailored treatment plans, significantly improving outcomes for rare and aggressive forms of leukemia. This approach holds promise for personalized medicine, ensuring each child receives optimal, life-saving care.
A woman wearing headphones and a red sweater is stretching her arms in the woods.
By Kathleen Mackay July 29, 2024
Notable Labs is transforming cancer treatment with its innovative combination therapy approach. By leveraging its Predictive Precision Medicine Platform (PPMP), Notable identifies optimal drug combinations tailored to individual patients. This methodology aims to reduce the development of resistant cancer cells and allows each drug to be used at its best dosage without intolerable side effects. The platform has shown impressive predictive accuracy in clinical trials, particularly for pediatric leukemia. Notable's commitment to precision medicine offers new hope for patients with high unmet medical needs, driving better treatment outcomes and enhancing quality of life.
Two little girls are sitting at a table painting with brushes.
By Fabian Goguta July 29, 2024
Notable Labs leverages predictive precision medicine to revolutionize cancer treatment, particularly pediatric leukemia. Their Predictive Medicine Platform (PMP) uses advanced technologies like flow cytometry and machine learning to analyze patient-specific cancer cell responses, offering highly accurate predictions for effective treatments. Clinical validation studies have shown a 97% precision in predicting responders. Collaborations with renowned institutions like Texas Children’s Hospital and UCSF further highlight Notable's commitment to improving pediatric oncology outcomes, making personalized, rapid, and effective cancer treatments a reality.
A woman and a little girl are sitting on the floor.
By Divya Narasimhan, MSc July 29, 2024
Precision medicine is revolutionizing pediatric leukemia treatment by offering tailored therapies based on individual genetic profiles. Notable Labs’ predictive precision medicine platform, driven by machine learning, is at the forefront of this transformation. With a 95% accuracy rate, this technology identifies the most effective treatments for rare and aggressive leukemia subtypes, such as pAML and JMML, ensuring better outcomes. This blog explores the advanced technological foundations, life-saving impact, and promising future of Notable Labs' approach in personalized cancer care for children.
A person is holding a baby 's hand on a bed.
By Dr. David Letsa July 29, 2024
Notable Labs, founded by Matthew De Silva, emerged from his personal quest to find better treatments for glioblastoma after his father's diagnosis. Partnering with Dr. Thomas Bock, De Silva's vision turned into a biotech startup revolutionizing cancer treatment through its Predictive Precision Medicine Platform (PPMP). The company's leadership team includes industry veterans like Dr. Joseph Wagner, Dr. Glenn Michelson, and Scott McPherson. Headquartered in Foster City, California, Notable Labs collaborates with top hospitals and leverages cutting-edge drug screening technology to deliver personalized cancer therapies, significantly improving patient outcomes.
A microscope is sitting on top of a table in a laboratory.
By Dr. Anjaney Kothari July 29, 2024
Given the complexity of the biological mechanisms that underlie cancer, it is prudent to identify and target more than one Achilles’ heel to attack this multifactorial disease. This can be achieved by employing combination therapy, an approach to cancer treatment that combines multiple therapeutic agents to improve patient outcomes. Notable Labs is at the forefront of revolutionary advancements in combination therapy, one noteworthy example being its long-standing collaboration with Syros Pharmaceuticals. For Syros, Notable developed a highly efficient predictive biological test to screen patients for the clinical trial of a combination therapy against non-acute promyelocytic leukemia (APL) acute myeloid leukemia (AML). Notable Labs’ innovative approach to combination therapy holds immense promise for significantly improving cancer treatment outcomes despite current limitations in commercial pursuit. This blog dives into the science behind the promise of combination therapy, how Notable is contributing toward the evolution of this technology, and why the company’s Board of Directors is excellently positioned to advance this field in the future. Notable Labs' investigation into combination therapy against cancer is backed by decades of scientific research. Combination therapy holds immense promise in the fight against cancer because of its ability to additively or synergistically target two or more cancer pathways. Due to its multi-target approach, combination therapy is also an effective strategy to overcome anti-cancer drug resistance. By collaborating with Syros in 2017, Notable Labs contributed to the phase II clinical trial of a therapy combining the drugs tamibarotene and azacitidine against non-APL AML. For this multi-arm monotherapy and combination therapy trial, Notable developed a blood-based biomarker test to help predict patient response to treatment. Specifically, Notable was involved in conducting ex vivo experiments on peripheral blood mononuclear cells (PBMCs) isolated from the blood samples of non-APL AML patients. Harnessing the power of high-throughput flow cytometry, these experiments revealed that a 72-hour ex vivo exposure of PBMCs to tamibarotene upregulates various markers of myeloid cell differentiation, including the RARα pathway target CD38. Importantly, treatments that can promote myeloid cell differentiation are known to be effective against some subtypes of AML. Therefore, by testing a patient’s blood sample using Notable’s ex vivo approach, it is possible to predict whether the patient is likely to respond well to tamibarotene in monotherapy and combination therapy. Indeed, Notable’s ex vivo assay became one of the strategies Syros adopted when screening patients for enrolment in the phase II clinical trial of tamibarotene (alone as well as in combination with azacitidine). Market Challenges Currently, cancer treatment – and thus, the oncology market as a whole – is faced with a three-pronged challenge. There are millions of non-responders who are not benefiting from chemotherapeutic drugs, thousands of compelling drugs that need to be shelved because of perceived non-response, and hundreds of promising candidate drugs that are struggling to navigate the drug development pipeline. Notable Labs is committed to resolving these challenges through its successfully tested predictive precision medicine pipeline, a significant application of which was demonstrated during the Syros clinical trial.  Notable Labs’ commitment is also one of the reasons why it has decided not to commercialize the combination therapy technology immediately. Notable wants to focus on refining the technology further, expanding its applications, and ensuring that it integrates seamlessly into existing healthcare systems. The company aims to develop more sophisticated prediction models and address regulatory and logistical challenges. This approach will help make Notable's technology accessible to a broader patient population, maximizing the life-saving potential of predictive diagnostics as well as combination therapy. Broader Applications The high-throughput nature of Notable’s ex vivo flow-cytometry-based predictive precision medicine pipeline has helped identify many powerful drug combinations to treat other cancers such as juvenile myelomonocytic leukemia. This pipeline also has great potential for identifying effective drug combinations and guiding patient enrolment in clinical trials of combination therapies for other cancers, including solid tumors. In the case of solid tumors, the Notable pipeline’s blood samples for ex vivo testing could be replaced by biopsy samples, circulating tumor cells, pleural effusion, or ascites, among other sampling options. Founding Story Notable’s CEO, Dr. Thomas Bock (MD, MBA), has ensured that the company is well-positioned to transform combination therapy for cancer. For decades, our CEO has worked on multiple dimensions of oncology, including precision medicine, prevention of inherited cancers, and cancer vaccines. At Notable, Dr. Bock combines his medical and business training to accomplish the company’s mission of dramatically improving patient outcomes and the success, speed, and cost of developing new medicines. Strength of the Board of Directors Notable’s esteemed Board of Directors boasts of more than 150 years of combined professional experience in premier life science companies. Our board members excel in medicine (Dr. Bock), pharmacology (Mr. Tuomo Pätsi), business (Dr. Bock), finance (Mr. Michael Rice, Mr. Peter Feinberg, Mr. Thomas Graney), media communications (Ms. Michele Galen), and law (Mr. Thomas Dubin), fostering a vibrant and eclectic environment for Notable to thrive. This diverse team of bona fide giants from the pharmaceutical and biotechnology sectors is set to efficiently guide Notable Labs on its path to success in combination therapy and beyond. Conclusion Combination therapy for cancer, aided by predictive methods, could significantly improve patient outcomes while also broadening the population of patients who can benefit from a given drug combination. Leading the charge in this direction, Notable Labs’ predictive precision medicine pipeline boasts of massive potential to not only identify effective drug combinations for combination therapy, but also guide patient enrolment in clinical trials through predictive screening. Moving ahead, Notable’s technology is set to transform the treatment of multiple types of cancer by ensuring positive patient outcomes of personalized combination therapies in shorter times and at lower costs. Additional Data Points AML statistics (American Cancer Society): estimated 20,800 new diagnoses and 11, 220 deaths in the US in 2024. Success stories and collaborations in the field of combination therapy: Notable’s collaboration with Syros to develop a predictive test for patient response to monotherapy and combination therapy. Potential impact on cancer treatment outcomes: Combination therapy, aided by predictive methods, has the potential to enhance patient outcome while also broadening the population of patients who can benefit from a given combination of drugs. Future directions for research and development: AML treatment strategies must pivot towards personalized/precision medicine because of overwhelming heterogeneity of the disease. References Combination therapy in combating cancer . (2017). Oncotarget Notable’s collaboration with Syros . (2017). Notable Labs + Syros Differentiation therapy for myeloid malignancies: beyond cytotoxicity . (2021). Blood Cancer Journal New strategies to treat AML: novel insights into AML survival pathways and combination therapies . (2021). Leukemia Precision oncology using ex vivo technology: a step towards individualised cancer care? . (2022). Expert Reviews in Molecular Medicine Targeting RARA overexpression with tamibarotene, a potent and selective RARα agonist, is a novel approach in AML . (2023). Blood Advances Notable Labs’ JMML data . (2023). Notable Labs Key statistics for acute myeloid leukemia (AML) . (2024). American Cancer Society About the Author Dr. Anjaney Kothari is a scientific writer and researcher with a decade of experience in biomedical research. He completed his Ph.D. in Biomedical Engineering from Virginia Tech (USA) in 2019, developing and characterizing holistic in vitro and ex vivo models of hepatic and gastrointestinal toxicity. He has since been working as a freelance writer and researcher for companies operating in diverse niches, including biotechnology and biopharmaceuticals. Disclaimer The content of these blogs reflects the research and opinions of the individual authors and does not necessarily represent the views or positions of Notable Labs or its affiliates. The information provided is for educational and informational purposes only and should not be construed as medical, legal, or financial advice. Notable Labs makes no representations as to the accuracy, completeness, or validity of any information in these blogs and will not be liable for any errors, omissions, or any losses, injuries, or damages arising from their use. These blogs may reference third-party research, studies, or resources. Notable Labs does not endorse or assume responsibility for the content or practices of these third parties. Any reliance on the information provided is at the reader's own risk. For biotechnology and pharmaceutical content, note that ongoing research and clinical trials may change the context and results discussed. Always refer to the latest research and guidelines from reputable sources.
More Posts
Share by: